Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q45968368

about

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile.Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center.The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies.Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas.Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.Allogeneic transplantation in the UK: an aggregation of marginal gains?The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials.Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma.Pharmacotherapeutic Management of Pediatric Lymphoma.Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

P2860

Q26770716-CAE83E9B-A2A7-4EFA-BE08-EA61AB4F0272 Q26999011-2E1C17E3-87AA-4498-9CCA-87FA14B46D40 Q27022992-73E5FA62-75E5-4815-9859-A3C2350D0D64 Q28067102-E7EA8EC3-CB88-4679-B01E-3D4C49122160 Q33404875-82F1E71E-FFE3-413D-9456-EDDD69EEA60D Q34975409-79F4E374-FF36-4888-B0CC-B876CFD5D47E Q35213027-31FC5EC9-0C98-4F4D-96FD-CE026FD90A6C Q35694050-20BE942B-EDC7-4797-A1B3-A03C8B3FB579 Q35825529-C8EB0C96-C4E4-4C23-89F2-4AC55B139ECA Q36055223-CBA4126F-4375-4281-AA9F-4C501B9065B3 Q36310347-AEE62AB3-77EB-46E2-BD5F-19A34C4A792F Q36979074-3C37B157-90F3-46C1-A0D8-B587DA5CF09F Q37144910-452E8B59-D711-43EF-9097-E692E42AB033 Q37609957-902D664E-DEDA-4D79-A2F9-0D4131219DF5 Q37894465-40F868DE-C72D-42C8-90AF-658E1216582A Q38099028-CE810A18-76B4-4B1D-BB4A-548094125431 Q38103578-AFB47271-3A36-46AF-B66D-43E829A80950 Q38105131-E6B5325D-1777-42DF-AB56-44C149521C5F Q38124363-96D20C80-2B72-4067-B9AA-DD13EEB2834B Q38206138-C5BFE366-D543-456E-94E1-2B8B544C0733 Q38664909-158E0A6D-852B-45E2-A045-6B34624F53D4 Q39431833-F61B04E9-3CAB-4C70-9FC5-5ADB10C805D5 Q40291708-6A492EE6-4598-4F01-92E4-F12F220DF8C1 Q41336256-D574C039-F2EF-43C7-B8AC-1656D73BDCAD Q42149544-3DD15150-ABF6-4A0E-8918-1C7472C9FA8C Q44407363-DCD038E0-B7F3-493C-9CDE-5C60B0E7D316 Q45396691-15575CBE-6D88-44FD-A77C-1B1E61EFEDAA Q48321203-33977386-BD1C-40F0-879F-32A6C381FB2B Q50994207-A17110BA-196E-44AE-A0FE-E3AB26C8023B Q53315058-A78BC211-18B8-45CF-B9E4-441D20B9A0CB Q56461161-4113AE90-0E97-4FA0-81D4-FABF40239978

P2860

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q45968368

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@en

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@nl

type

label

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@en

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@nl

prefLabel

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@en

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@nl

P1433

Q45968368-6BA71ACB-14C9-45C1-8019-BE36DC8BCED8

P1476

Q45968368-730D81B4-ED88-4CC4-BBB3-80D423B18134

P2093

Q45968368-14D670B2-B52B-4B3E-AD99-2B0FE4AEC58B

Q45968368-35AAE660-AF0D-4AE1-8B5F-4D9068715F69

Q45968368-49DC0870-60C3-4925-B980-22854A3BD726

Q45968368-4B5B7A4F-F463-4E2F-878A-4F342C84116C

Q45968368-5505B76F-C35B-499C-BF72-5905F774423F

Q45968368-7F5E289B-1AD7-4194-AD1C-B5D3626B4730

Q45968368-A492094D-37DC-4AC8-85BC-7FC96DBD9DC5

Q45968368-BE9FF1B7-04C3-4E7F-B9FB-05E5C7B8D260

Q45968368-E8CF56AC-C96D-4AAF-91BB-5E47CDCCEA69

Q45968368-F6ED8529-EBF1-42E9-8EA8-A5D5CB4EE18F

P304

Q45968368-64BFE3CE-BF97-4B2D-9AAB-4AE1BC76E608

P31

Q45968368-54DA2D4F-B5E8-4B22-86F7-00346EA5E9D8

P356

Q45968368-0E1E5540-EE24-4E1C-8450-DB8EBA05AC1C

P407

Q45968368-8CC26CE4-4672-4882-8D22-B110E7D52473

P433

Q45968368-9BA3CF4E-7230-4124-B3E9-2A3FDB0977C1

P478

Q45968368-9BC342E6-7C5B-4BB0-AEED-7D90DD9D2618

P50

Q45968368-2201CC0B-796D-4984-9564-440908830A54

Q45968368-34EFD43C-2717-4ABC-BF7B-DD2206C8B590

P577

Q45968368-9CCD2F9D-A73E-43A6-A74F-FC8EB06C3764

P698

Q45968368-B346EABC-F7FC-4DD0-8847-DB5F857ECA72

P921

Q45968368-3DD5A60F-CA3D-46DC-86D4-A4E22DB61547

P356

JCO.2010.32.1711

P1433

Journal of Clinical Oncology

P1476

Donor lymphocyte infusions mod ...... tation for Hodgkin's lymphoma.

@en

P2093

Adele Fielding

http://www.w3.org/2001/XMLSchema#string

Anthony H Goldstone

http://www.w3.org/2001/XMLSchema#string

David C Linch

http://www.w3.org/2001/XMLSchema#string

Irfan Kayani

http://www.w3.org/2001/XMLSchema#string

Karl S Peggs

http://www.w3.org/2001/XMLSchema#string

Kirsty J Thomson

http://www.w3.org/2001/XMLSchema#string

Noha Edwards

http://www.w3.org/2001/XMLSchema#string

Panagiotis Kottaridis

http://www.w3.org/2001/XMLSchema#string

Rachael Hough

http://www.w3.org/2001/XMLSchema#string

Stephen Mackinnon

http://www.w3.org/2001/XMLSchema#string

P304

971-978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.1711

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Ronjon Chakraverty

P577

2011-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21282545

http://www.w3.org/2001/XMLSchema#string

P921